

A FUTURE VISION FOR THE SPECIALTY DRUG MARKETPLACE



The National Alliance, working with its coalitions, is promoting a "Five Rights" framework for specialty drug stakeholders to improve value for healthcare purchasers

RAISING THE STAKES

Specialty drugs are one of the fastest growing areas of spending for both private & public purchasers

- Some drug prices grow at 500% or more
- US buys more and pays more than any other country



High Cost, High Variation, High Waste

- Variation in management of formulary, specialty list, utilization, clinical, pipeline, etc.
- Wide variation in price 2x-25x
- Up to 30% not filled, 50% not taken, 10% admissions due to poor adherence

Complexity, Middlemen, Conflicts

- Employers are often left without the needed data and information to manage specialty drug use and cost
- Our "stewards" contribute to these issues by adding complexity and cost to an inefficient supply chain.



High Value

THE FIVE RIGHTS FRAMEWORK



Right Drug



Right Price



Right Place



Right Data



Right Support

- Base practices and decisions on clinical efficacy and safety independent of conflicted interests/PBMs accept ERISA fiduciary status.
- Cover testing that supports improved assessment of correct drug, doses and duration of treatment for specific patient.
- Require purchaser transparency and engagement on key issues and National Drug Codes used by all providers, in all settings related to: prior authorization, utilization management, payment & rebates, claim level reporting, data analysis, provider contracts, patient outcomes, and quality improvement
- Align value based contracting with performance and adherence to high value drugs with correct doses and duration consistent with guidelines.
- Require cost parity or benefit differentials across sites of care for same drugs and services.
- Support patients on drug administration and needed emotional/social support to increase adherence and improve outcomes.
- Discontinue conflicting practices such as low value coupon programs, drug price increases more than Consumer Price Index, and exclusion of high value delivery options.